THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.

Filip Janku; Raghad Abdul-Karim; Arun Azad; Johanna Bendell; Gerald Falchook; Hui K. Gan; Tira Tan; Judy S. Wang; Cheng Ean Chee; Lina Ma; Jill Mooney; Neyssa Marina; Giovanni Abbadessa; Marcos Milla; Tarek Meniawy

doi:10.1158/1538-7445.AM2021-LB041

THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.

Filip Janku, Raghad Abdul-Karim, Arun Azad, Johanna Bendell, Gerald Falchook, Hui K. Gan, Tira Tan, Judy S. Wang, Cheng Ean Chee, Lina Ma, Jill Mooney, Neyssa Marina, Giovanni Abbadessa, Marcos Milla, Tarek Meniawy

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Cancer Research
Volume	81
Issue number	13
DOIs	https://doi.org/10.1158/1538-7445.AM2021-LB041
Publication status	Published - Jul 2021
Event	AACR Annual Meeting 2021 - , Virtual Duration: 9 Apr 2021 → 14 Apr 2021 https://www.aacr.org/meeting/aacr-annual-meeting-2021/

Access to Document

10.1158/1538-7445.AM2021-LB041

Cite this

Janku, F., Abdul-Karim, R., Azad, A., Bendell, J., Falchook, G., Gan, H. K., Tan, T., Wang, J. S., Chee, C. E., Ma, L., Mooney, J., Marina, N., Abbadessa, G., Milla, M., & Meniawy, T. (2021). THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study. Cancer Research, 81(13). https://doi.org/10.1158/1538-7445.AM2021-LB041

@article{af7dc7e94f894b2eabd173131c652f86,

title = "THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.",

author = "Filip Janku and Raghad Abdul-Karim and Arun Azad and Johanna Bendell and Gerald Falchook and Gan, {Hui K.} and Tira Tan and Wang, {Judy S.} and Chee, {Cheng Ean} and Lina Ma and Jill Mooney and Neyssa Marina and Giovanni Abbadessa and Marcos Milla and Tarek Meniawy",

year = "2021",

month = jul,

doi = "10.1158/1538-7445.AM2021-LB041",

language = "English",

volume = "81",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "13",

note = "AACR Annual Meeting 2021 ; Conference date: 09-04-2021 Through 14-04-2021",

url = "https://www.aacr.org/meeting/aacr-annual-meeting-2021/",

}

Janku, F, Abdul-Karim, R, Azad, A, Bendell, J, Falchook, G, Gan, HK, Tan, T, Wang, JS, Chee, CE, Ma, L, Mooney, J, Marina, N, Abbadessa, G, Milla, M & Meniawy, T 2021, 'THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.', Cancer Research, vol. 81, no. 13. https://doi.org/10.1158/1538-7445.AM2021-LB041

THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study. / Janku, Filip; Abdul-Karim, Raghad; Azad, Arun et al.
In: Cancer Research, Vol. 81, No. 13, 07.2021.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors

T2 - AACR Annual Meeting 2021

AU - Janku, Filip

AU - Abdul-Karim, Raghad

AU - Azad, Arun

AU - Bendell, Johanna

AU - Falchook, Gerald

AU - Gan, Hui K.

AU - Tan, Tira

AU - Wang, Judy S.

AU - Chee, Cheng Ean

AU - Ma, Lina

AU - Mooney, Jill

AU - Marina, Neyssa

AU - Abbadessa, Giovanni

AU - Milla, Marcos

AU - Meniawy, Tarek

PY - 2021/7

Y1 - 2021/7

U2 - 10.1158/1538-7445.AM2021-LB041

DO - 10.1158/1538-7445.AM2021-LB041

M3 - Abstract/Meeting Abstract

SN - 0008-5472

VL - 81

JO - Cancer Research

JF - Cancer Research

IS - 13

Y2 - 9 April 2021 through 14 April 2021

ER -